Literature DB >> 23436024

Viral hepatitis: review of arthritic complications and therapy for arthritis in the presence of active HBV/HCV.

Dimitrios Vassilopoulos1, Leonard H Calabrese.   

Abstract

Chronic infection with hepatitis B (HBV) or C (HCV) virus, which currently affect approximately 7 % of the world population, is encountered with the same frequency among patients with arthritis starting biological or non-biological disease-modifying anti-rheumatic drugs (DMARDs). Treatment with biological agents, including anti-tumor necrosis factor agents, rituximab, and abatacept, without appropriate antiviral therapy has been associated with reactivation of HBV infection which in some cases can lead to life-threatening complications, indicating the need for appropriate screening and treatment of these patients. In this review, the latest data regarding HBV or HCV-related arthritic complications and treatment of rheumatic diseases in the presence of chronic HBV or HCV infection will be critically presented.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23436024     DOI： 10.1007/s11926-013-0319-1

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN： 1523-3774            Impact factor:   4.686


  52 in total

1.  Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy.

Authors:  Jorge Méndez-Navarro; Kathleen E Corey; Hui Zheng; Lydia L Barlow; Jae Young Jang; Wenyu Lin; Hong Zhao; Run-Xuan Shao; Steven L McAfee; Raymond T Chung
Journal:  Liver Int       Date:  2010-08-25       Impact factor: 5.828

2.  Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

Authors:  D Vassilopoulos; A Apostolopoulou; E Hadziyannis; G V Papatheodoridis; S Manolakopoulos; J Koskinas; E K Manesis; A I Archimandritis
Journal:  Ann Rheum Dis       Date:  2010-05-14       Impact factor: 19.103

3.  Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection.

Authors:  Ioannnis Mitroulis; Chrisoula Hatzara; Anna Kandili; Emilia Hadziyannis; Dimitrios Vassilopoulos
Journal:  Ann Rheum Dis       Date:  2012-08-28       Impact factor: 19.103

4.  Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.

Authors:  David Saadoun; Mathieu Resche Rigon; Damien Sene; Benjamin Terrier; Alexandre Karras; Laurent Perard; Yoland Schoindre; Brigitte Coppéré; François Blanc; Lucile Musset; Jean-Charles Piette; Michele Rosenzwajg; Patrice Cacoub
Journal:  Blood       Date:  2010-05-03       Impact factor: 22.113

5.  No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.

Authors:  Anna Rita Giardina; Donatella Ferraro; Francesco Ciccia; Angelo Ferrante; Rosa Di Stefano; Antonio Craxì; Giovanni Triolo
Journal:  Clin Exp Rheumatol       Date:  2012-08-30       Impact factor: 4.473

6.  Hepatitis C virus-related arthritis: characteristics and response to therapy with interferon alpha.

Authors:  E Zuckerman; D Keren; M Rozenbaum; E Toubi; G Slobodin; A Tamir; J E Naschitz; D Yeshurun; I Rosner
Journal:  Clin Exp Rheumatol       Date:  2000 Sep-Oct       Impact factor: 4.473

7.  Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.

Authors:  Franco Dammacco; Felicia Anna Tucci; Gianfranco Lauletta; Pietro Gatti; Valli De Re; Vincenza Conteduca; Silvia Sansonno; Sabino Russi; Maria Addolorata Mariggiò; Maria Chironna; Domenico Sansonno
Journal:  Blood       Date:  2010-03-22       Impact factor: 22.113

Review 8.  An overview of occult hepatitis B virus infection.

Authors:  Zeinab Nabil Ahmed Said
Journal:  World J Gastroenterol       Date:  2011-04-21       Impact factor: 5.742

9.  Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients.

Authors:  Clodoveo Ferri; Marco Sebastiani; Dilia Giuggioli; Massimiliano Cazzato; Giovanni Longombardo; Alessandro Antonelli; Rodolfo Puccini; Claudio Michelassi; Anna Linda Zignego
Journal:  Semin Arthritis Rheum       Date:  2004-06       Impact factor: 5.532

10.  Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.

Authors:  Anna S F Lok; John W Ward; Robert P Perrillo; Brian J McMahon; T Jake Liang
Journal:  Ann Intern Med       Date:  2012-05-15       Impact factor: 25.391
View more
  3 in total

Review 1.  Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.

Authors:  Francesca De Nard; Monica Todoerti; Vittorio Grosso; Sara Monti; Silvia Breda; Silvia Rossi; Carlomaurizio Montecucco; Roberto Caporali
Journal:  World J Hepatol       Date:  2015-03-27

Review 2.  HCV Treatments and Their Integration Into Rheumatology.

Authors:  Dimitrios Vassilopoulos; Leonard H Calabrese
Journal:  Curr Rheumatol Rep       Date:  2015-08       Impact factor: 4.592

Review 3.  B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.

Authors:  Md Yuzaiful Md Yusof; Edward M Vital; Maya H Buch
Journal:  Curr Rheumatol Rep       Date:  2015-10       Impact factor: 4.592
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.